| 引用本文: | 范磊,孙婧,周松阳,王凯,黄鹤,崔诗允.脾多肽注射液辅助治疗对结直肠癌患者T淋巴细胞、免疫因子的影响[J].中国现代应用药学,2020,37(7):847-850. |
| FAN Lei,SUN Jing,ZHOU Songyang,WANG Kai,HUANG He,CUI Shiyun.Effects of Spleen Polypeptide Injection Adjuvant Therapy on T Lymphocyte and Immunologic Factors in Patients with Colorectal Carcinoma[J].Chin J Mod Appl Pharm(中国现代应用药学),2020,37(7):847-850. |
|
| 本文已被：浏览 1852次 下载 1496次 |
码上扫一扫！ |
|
|
| 脾多肽注射液辅助治疗对结直肠癌患者T淋巴细胞、免疫因子的影响 |
|
范磊1, 孙婧2, 周松阳1, 王凯3, 黄鹤4, 崔诗允2
|
|
1.南京中医药大学附属中西医结合医院普外科, 南京 210000;2.南京医科大学第一附属医院肿瘤科, 南京 210000;3.南京医科大学, 第一临床医学院, 南京 210000;4.南京医科大学, 口腔医学院, 南京 210000
|
|
| 摘要: |
| 目的 分析脾多肽注射液辅助治疗对结直肠癌患者T淋巴细胞及免疫因子的影响，为结直肠癌患者的临床治疗提供参考。方法 选取2016年3月-2018年4月在南京医科大学第一附属医院诊断且符合纳入标准的88例伴有不可切除肝转移的晚期结直肠癌患者为研究对象，采用随机数字表法将其分为观察组和对照组，每组各44例，对照组患者行常规化疗，观察组在对照组基础上加用脾多肽注射液治疗，比较2组患者的临床疗效、T淋巴细胞及免疫因子水平。结果 观察组患者的临床治疗总有效率明显高于对照组（P<0.05）；治疗前，2组患者的T淋巴细胞及免疫因子水平均无显著差异，治疗后，2组患者的CD3+、CD4+、CD4+/CD8+及自然杀伤细胞水平均明显高于治疗前（P<0.05），且观察组明显高于对照组（P<0.05），2组患者的CD8+、可溶性白细胞介素-2受体及白细胞介素-8水平均明显低于治疗前（P<0.05），且观察组明显低于对照组（P<0.05）。结论 脾多肽注射液辅助治疗可提高结直肠癌患者临床疗效，改善患者T淋巴细胞及免疫因子水平。 |
| 关键词: 脾多肽注射液 结直肠癌 T淋巴细胞 免疫因子 |
| DOI：10.13748/j.cnki.issn1007-7693.2020.07.014 |
| 分类号:R969.4 |
| 基金项目:国家自然科学基金青年基金项目（81502611） |
|
| Effects of Spleen Polypeptide Injection Adjuvant Therapy on T Lymphocyte and Immunologic Factors in Patients with Colorectal Carcinoma |
|
FAN Lei1, SUN Jing2, ZHOU Songyang1, WANG Kai3, HUANG He4, CUI Shiyun2
|
|
1.Department of General Surgery, Hospital of Integrated Chinese and Western Medicine Affiliated to Nanjing University of Traditional Chinese Medicine, Nanjing 210000, China;2.Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210000, China;3.Nanjing Medical University, First Clinical Medical College, Nanjing 210000, China;4.Nanjing Medical University, School of Stomatology, Nanjing 210000, China
|
| Abstract: |
| OBJECTIVE To analyze the effects of spleen polypeptide injection adjuvant therapy on T lymphocyte and immunologic factors in patients with colorectal carcinoma, to provide reference for clinical treatment of patients with colorectal carcinoma. METHODS A total of 88 advanced colorectal carcinoma patients with unresectable liver metastasis who were dignoised and inclusion criteria in the First Affiliated Hospital of Nanjing Medical University were selected from March 2016 to April 2018, and they were divided into observation group(n=44) and control group(n=44) according to the random number table method. Patients in the control group were treated with conventional chemotherapy, and the observation group was treated with spleen polypeptide injection on the basis of the control group. The clinical effect, the levels of T lymphocyte and immunologic factors were compared between the two groups. RESULTS The total effective rate of clinical treatment in observation group was obviously higher than that of control group (P<0.05). Before treatment, there were no significantly differences in the level of T lymphocyte and immunologic factors between the two groups. After treatment, the level of CD3+, CD4+, CD4+/CD8+ and natural killer in the two groups were obviously higher than those of before treatment(P<0.05), and the observation group was obviously higher than the control group(P<0.05). The level of CD8+, soluble interleukin-2 receptor and interleukin-8 in the two groups were obviously lower than those of before treatment(P<0.05), and the observation group was obviously lower than the control group(P<0.05). CONCLUSION The spleen polypeptide injection adjuvant therapy can improve the clinical effects of patients with colorectal carcinoma, and improve the levels of T lymphocyte and immunologic factors. |
| Key words: spleen polypeptide injection colorectal carcinoma T lymphocyte immunologic factors |
